Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Feedback Plc LSE:FDBK London Ordinary Share GB0003340550 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 0.625 0.60 0.65 0.625 0.625 0.63 0.00 07:31:05
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Electronic & Electrical Equipment 0.3 -2.1 -0.2 - 17

Feedback Share Discussion Threads

Showing 13426 to 13448 of 13450 messages
Chat Pages: 538  537  536  535  534  533  532  531  530  529  528  527  Older
DateSubjectAuthorDiscuss
28/6/2022
13:11
"Feedback Medical uses Zoho Flow to automate key workflows and eliminate manual work" Adam Kentrop, Senior Systems Engineer, Feedback Medical Https://www.zoho.com/flow/customers/feedback-medical.html Https://en.wikipedia.org/wiki/Zoho_Corporation
lr2
27/6/2022
13:54
Thanks LR2, post 10019. Not really sure what the other links were showing about Bleepa. So average time for a referral was improved by 56% and to complete a referral by 49% Sounds good to me but does anyone know how that compares to any other referral system?
ged5
27/6/2022
10:53
Cheers LR.
digger2779
27/6/2022
08:40
Four more Bleepa references via a search made courtesy of Private Ryan over on the other place. Https://gut.bmj.com/search/bleepa%20jcode%3Agutjnl
lr2
27/6/2022
04:14
Good info LR2. Thank you. Manchester and Oldham.
ducatiman
27/6/2022
01:00
Bleepa references within the below link. P256 Improving processes and response times for gastroenterology referrals Https://gut.bmj.com/content/71/Suppl_1/A165.2
lr2
22/6/2022
18:06
Thanks for that update SSB, someone else told me the same thing recently. I had a top up recently at 0.64p as I believe there will be news of more sales of Bleepa / CareLocker in the next few weeks. I see BIRD had a better day, today. Here's hoping we both have better times ahead of us.
lr2
22/6/2022
17:46
LR, the chart filled the gap, FYI. Not saying I would be buying but that was a magnet. BWTFDIK
sideshowbull
20/6/2022
12:27
Bleepa has a TB screening opportunity in Wales. Three diagnosed with TB after person dies at Welsh university campus Https://www.walesonline.co.uk/news/wales-news/tb-outbreak-hywel-dda-lampeter-24253925
lr2
16/6/2022
23:07
LR2 - that one works thanks. So in 5 years we will all be millionaires!!! I've just got to keep the grim reaper at bay for a bit longer than I was planning haha.
digger2779
16/6/2022
17:33
Hi Digger, The video appears to have a new link for some reason. Try this. Https://youtu.be/_vHNlxPOiDU
lr2
16/6/2022
17:19
Hi Digger, I listened to it twice and don't recall anything out of the ordinary on it. Hi TooDeep, Take out the £10 mil cash and we have a company capable of producing £882k revenue from existing sources. Products of company are thus valued at around 8 times yearly revenue based on last 6 month revenue. Assume 3-4 new UK groups on board in next 6 months (hopefully more) and TB testing program in Odisha gets the OK to go statewide then (Odisha pop 45 mil) 5% population (ultimately aiming at 20% a year) testing is 2.25 mil at £2 with scans captured on CareLocker, company gets revenue of £882k x 2 = £1.75 plus £4.5 mil. Total revenue £6.25 mil. £6.25 mil x 8 for MCAP calc = £50 mil. 1.8p a share. The following is from the Year End Trading Update and appears to have been overlooked by many today. I suspect that it should not be as a move into 'further sites' will soon have a very positive effect on profits. "Feedback also made significant progress in India with its cloud TB screening pilot service going live at the Evangelical Hospital Khariar in Odisha in March, following which over 250 patients have now gone through the workflow. This pilot is being used to generate evidence which will enable the Company to expand into further sites and pursue opportunities to commercialise the offering." Definitely forward looking of me with a bunch of assumptions that need to materialise but, in my eyes, not impossible to obtain. I guess we will know more in six months time. Edit: original figure of 1.6p was wrong as my original population figures for Odisha were 5 years out of date.
lr2
16/6/2022
16:47
LR -16 Jun '22 - 12:42 - 10003 of 10011 0 1 0 Tom Oakley and the lovely Katie. Https://youtu.be/gURNDnl4k4s The video has been removed. Was it any good?
digger2779
16/6/2022
16:10
Thank you very much. So would you say that 200% revenue growth is an easy target to get to say £2.5m for year to May 2023? Sounds like a definite maybe, subject to new groups coming on board? Sill not sure how the share price would re-rate to 1.6p in the near term though to give an MCAP of some £42m or +150% from today? Surely the revenue numbers would need to be closer to say £7m p.a to get an MCAP of 5x Revenues? £0.007 Share Price 2,667,000,000 No of Shares £17,335,500 Mcap £0.016 Share Price 2,667,000,000 No of Shares £42,672,000 MCAP
intoodeep
16/6/2022
14:17
Guys appreciate the comments. Annual income of £0.6m to May 2022. Some deferred Income for next year £0.1m Cash in bank of £10.1m MCAP £17m If sales were to double to say £1.2m how can the MCAP be re-rated in this market. MCAP doesn't look low, so what am I missing?
intoodeep
16/6/2022
14:06
Thanks, will edit. No, I'm thinking 80k sales will be included in revenues in future results. They've talked about deferred sales in the past somewhere. Probably an RNS but I have a vague recollection of an explanation in one of the interviews.
ged5
16/6/2022
14:05
Sales during the current financial year - £670k. Revenue for the current financial year - £590k Sales for the next financial year - £80k. That's how I see it. They take revenue in the month it is due.
lr2
16/6/2022
13:51
Understood but it's actually £590k revenues(not £509k) v £670k sales diff + £80K between sales and revenues. Are you thinking that none of the £670k sales were counted in the revenues of £590k?
intoodeep
16/6/2022
13:31
Intoodeep, you ask:- "Why are revenues +105% and sales +280% numbers so different?" If you read the RNS more carefully you will see that some sales are deferred to future trading periods. So yes the revenue of 590K is accounted this year but they've made 670K sales in the trading period to be included in future trading periods revenues. So sales were better than I expected. Good, better progress than I first thought.
ged5
16/6/2022
12:57
Thanks LR2 "In partnership with Qure.AI" So has it moved on from the MOU? Sleepless nights and big meals?
ged5
16/6/2022
12:42
Tom Oakley and the lovely Katie. Https://youtu.be/gURNDnl4k4s
lr2
16/6/2022
12:38
Bank of England have raised interest rate to 1.25%. That's not going to dampen the inflation rate.
lr2
16/6/2022
11:59
Who writes this stuff? Why are revenues +105% and sales +280% numbers so different? And what about operating losses which last year were £2m. As per the announcement dated 01 June 2022, trading for FY22 was materially ahead of market expectations with revenue expected to be reported as c.£0.59m (FY21: £0.29m), up approximately 105%, following a significant increase in sales(1) to £0.67m (FY21: £0.18m), up approximately 280%.
intoodeep
Chat Pages: 538  537  536  535  534  533  532  531  530  529  528  527  Older
ADVFN Advertorial
Your Recent History
LSE
FDBK
Feedback
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220629 13:46:56